Keywords: Abilify, Seroquel, Bipolar disorder, Bristole-Myers Squbb, Otsuka, AstraZeneca, Decision Resources

First-line use of Abilify more than doubles over past year for newly-diagnosed patients with bipolar disorder

Article | 19 November 2010

• Print This

First-line use of Bristol Myers-Squibb(NYSE: BMY)/Otsuka's (TYO: 4523) Abilify (aripiprazole) has increased over the past year in newly-diagnosed patients ...

Enjoying this article? To continue reading you need to login or subscribe.